AMN107

PreclinicalSmall molecule

Novartis

AMN107 is one of 20 small molecule programs targeting Myeloid Leukemia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Myeloid LeukemiaActive, not recruiting

Myeloid LeukemiaPreclinical

Active, not recruiting

Competition

Competitive Landscape

24 competitors in Myeloid Leukemia

#DrugCompanyPhaseTrials

Gleevec

Novartis

Approved

38 2

Sprycel

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

35 3

Tasigna

AAzurity Pharmaceuticals

Approved

25 4

Venclexta

AbbVie

Approved

2 5

Bosulif

PPrism Pharmaceuticals

Approved

10 6

Dacogen

Sun Pharmaceutical Industries, Inc.

Lynparza

Novantrone

1 9

Cerubidine

HHikma Pharmaceuticals LLC

Jakafi

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Newly Diagnosed1 trial

Trial Evaluating Nilotinib as Treatment for Newly Diagnosed CML Patients in Accelerated Phase.

Withdrawn· Novartis logo

Novartis·Phase 4·NCT01605981

Chronic Myelogenous Leukemia1 trial

Efficacy and Safety of Oral AMN107 in Adults With Chronic Myelogenous Leukemia Resistant and/or Intolerant to Imatinib Mesylate Therapy

Completed· Novartis logo

Novartis·Phase 2/3·NCT00264160·36 enrolled

Myeloid Leukemia1 trial

Expanded Access Program of AMN107 in Imatinib-resistant or Intolerant Adult Patients With Chronic Myeloid Leukemia

No longer available· Novartis logo

Novartis··NCT00302016

Gastrointestinal Stromal Tumor1 trial

Efficacy and Safety of AMN107 in Patients With GastroIntestinal Stromal Tumors (GIST) Who Have Failed Both Imatinib and Sunitinib

Completed· Novartis logo

Novartis·Phase 2·NCT00718562·35 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for AMN107. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AMN107 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AMN107. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Novartis

AMN107

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Newly Diagnosed1 trial

Chronic Myelogenous Leukemia1 trial

Myeloid Leukemia1 trial

Gastrointestinal Stromal Tumor1 trial

References

Drug Info

Quick Facts

Related News